Design, Development and Optimisation of a Nanobased Delivery System for Nephropathic Cystinosis

Apply and key information  

This project is funded by:

    • HSC R&D Division
    • Medical Research Council

Summary

Nephropathic cystinosis is a rare inherited disorder associated with progressive renal injury. Although the current treatment,  cysteamine,  reduces lysosomal cystine accumulation, additional strategies to protect renal function are needed. This research forms part of a larger US-ROI-NI tripartite that investigates molecular mechanisms of renal injury and develops new treatments. This proposed PhD will make a defined, chemistry-led contribution to its drug-delivery aim: designing, synthesising and optimising polymeric nanocarriers for the development of novel treatments for cystinosis.

Amphiphilic polymers offer an adaptable platform for micelles and polymersomes. Preliminary work has been on the synthesis and characterisation of suitable polymers, preparation of drug-loaded micelles with encouraging cell-based findings. This PhD will build on an established foundation while addressing substantial questions concerning polymer structure, nanocarrier architecture, drug loading, stability and release.

The student will design and synthesise a library of amphiphilic polymers and prepare reproducible nanoformulations. Polymer identity and composition will be characterised using nuclear magnetic resonance and mass spectrometry. Dynamic light scattering, surface-charge measurements and appropriate imaging will establish formulation size, dispersity and morphology. Analytical methods will quantify drug loading, encapsulation efficiency, stability and release kinetics, including evaluation of dual-drug formulations. Formulation variables will be systematically investigated to establish structure–property relationships and identify candidates with suitable physicochemical performance and biocompatibility.

Selected formulations will be evaluated in healthy and CTNS-deficient renal proximal tubular epithelial cell models, in collaboration with the wider team, to assess cytocompatibility and uptake. These data will inform formulation refinement. Optimised candidates will be supplied to consortium partners for advanced imaging and preclinical efficacy studies; those wider biological studies are not the primary focus of this PhD.

The project offers a coherent and independently examinable programme of polymer chemistry, pharmaceutical formulation and analytical characterisation with a clear translational application. It will develop expertise in synthesis, NMR, mass spectrometry, nanoparticle characterisation and quantitative drug analysis. A candidate with a strong chemistry background is therefore particularly appropriate. Access to complementary expertise at Dublin City University and the University of California, San Francisco provides a collaborative environment and a route for the resulting formulations to progress into disease-relevant testing.

Essential criteria

Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.

We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.

In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.

  • International applicants should hold, or expect to hold a relevant Masters Degree at a level equivalent to a distinction at Ulster
  • Research proposal of 1500 words detailing aims, objectives, milestones and methodology of the project
  • Experience using research methods or other approaches relevant to the subject domain

Desirable Criteria

If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.

  • International applicants should hold, or expect to hold, a First Class Honours Degree in a relevant subject area
  • Experience or knowledge of research methods or other approaches relevant to the subject domain
  • Work experience relevant to the proposed project
  • Experience of presentation of research findings

Equal Opportunities

The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.

Appointment will be made on merit.

Funding and eligibility

This project is funded by:

  • HSC R&D Division
  • Medical Research Council

PhD scholarships are available for this project to all applicants worldwide, regardless of residency or domicile, and will cover:

  • Tuition fees.
  • A maintenance allowance of approximately £22,459 per annum for three years, subject to satisfactory academic performance.
  • A Research Training Support Grant (RTSG) of approximately £3,000.

Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year, or part-time equivalent, funded from any source, including self-financing students, are NOT eligible to apply for an award.

Students in full-time employment are not eligible for an award.

Due consideration should be given to financing your studies.

Recommended reading

Gahl WA, Balog JZ, Kleta R. Cystinosis. New England Journal of Medicine. 2017;376:125–135.

Cherqui S, Courtoy PJ. The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives. Nature Reviews Nephrology. 2017;13(2):115–131.

Martin C, Aibani N, Callan JF, Callan B. Recent advances in amphiphilic polymers for simultaneous delivery of hydrophobic and hydrophilic drugs. Therapeutic Delivery. 2016;7(1):15–31.

Martin C, Dolmazon E, Moylan K, et al. A charge neutral, size tuneable polymersome capable of high biological encapsulation efficiency and cell permeation. International Journal of Pharmaceutics. 2015;481(1–2):1–8.

Martin C, Marino N, Curran C, McHale AP, Callan JF, Callan B. Cholesteryl to improve the cellular uptake of polymersomes within HeLa cells. International Journal of Pharmaceutics. 2016;511(1):570–578.

Aibani N, Nesbitt H, Marino N, et al. Electroneutral polymersomes for combined cancer chemotherapy. Acta Biomaterialia. 2018;80:327–340.

Aibani N, Khan TN, Callan B. Liposome mimicking polymersomes: A comparative study of the merits of polymersomes in terms of formulation and stability. International Journal of Pharmaceutics X. 2020;2:100040.

The Doctoral College at Ulster University

Key dates

Submission deadline
Friday 26 February 2027
12:00AM

Interview Date
April 27

Preferred student start date
13/09/2027

Applying

Apply Online  

Contact supervisor

Professor Bridgeen Callan

Other supervisors